�����ƽ��

In drug discovery, the respiratory system is both a therapeutic target and a critical site of exposure for inhaled and systemically administered compounds. Human airway and alveolar in vitro tissue models enable assessment of epithelial barrier function, inflammatory signaling, cytotoxicity, and tissue remodeling. Organoid and air-liquid interface (ALI) models further enhance the ability to study complex airway architecture and lung-specific biology.Together, these systems enable early evaluation of respiratory toxicity, compound delivery effects, and disease-relevant responses when incorporated as new approach methodologies (NAMs).

Respiratory models also strengthen your translational research and disease modeling. Physiologically relevant, human respiratory models that capture features of asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and other lung conditions allow you to study target validation and perform functional screening in lung-relevant contexts. Quantitative assessment of barrier integrity, secretory function, and inflammatory biomarkers improve the ability to predict clinical outcomes and support you to make more informed therapeutic development decisions.

Explore in vitro respiratory system tools for your NAM development.